Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.
about
Emerging drugs for immune thrombocytopenia (ITP).Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.Drugs in early clinical development for Systemic Lupus Erythematosus.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Recent advances and current state of immunotherapy in systemic lupus erythematosus.A critical review of clinical trials in systemic lupus erythematosus.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Update on Biologic Therapies for Systemic Lupus Erythematosus.T-cell-directed therapies in systemic lupus erythematosus.Systemic lupus erythematosus biomarkers: the challenging quest.Defective Suppressor of Cytokine Signaling 1 Signaling Contributes to the Pathogenesis of Systemic Lupus Erythematosus.Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience.
P2860
Q33439789-8B96D498-80E4-42DF-9582-07A779D1BF49Q33723903-2F35EFAC-0501-44FB-8C0B-67779ED1A361Q37324772-DC52526E-7AB8-4B30-A6CE-F08963B18D4AQ38690844-163A5160-1C03-4E2E-81A1-F588EA7BF165Q38747383-3553BC03-2535-4A3B-B92C-55700D47AA84Q38794663-42761704-49B6-45A4-A432-E0A8CBB234A6Q38833868-6AB903EE-F7CE-45A0-BA40-310763B57430Q38840646-A6657415-407C-48CB-B2A3-928B55F51D76Q38864797-A2329BF6-0E22-47BE-A2A1-4474B6007FD3Q38920440-C1BDFAC0-6AC9-45D4-BA2C-6A14B4A1D9FFQ39053118-3F2E6688-077F-4555-AEF0-C2A434BD5092Q47151871-BA941072-64AD-4988-8A85-BE17D9D9128AQ47552016-F076C779-6AE6-482A-9193-ECA3E95EE7D6Q50493859-26BE95DA-BEB6-4EC9-AA82-9883382A5D2D
P2860
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety and efficacy of hCDR1 ( ...... us: results of phase II study.
@ast
Safety and efficacy of hCDR1 ( ...... us: results of phase II study.
@en
type
label
Safety and efficacy of hCDR1 ( ...... us: results of phase II study.
@ast
Safety and efficacy of hCDR1 ( ...... us: results of phase II study.
@en
prefLabel
Safety and efficacy of hCDR1 ( ...... us: results of phase II study.
@ast
Safety and efficacy of hCDR1 ( ...... us: results of phase II study.
@en
P2860
P1476
Safety and efficacy of hCDR1 ( ...... us: results of phase II study.
@en
P2093
Daniel J Wallace
Murray B Urowitz
P2860
P304
P356
10.1136/LUPUS-2015-000104
P577
2015-08-11T00:00:00Z